MIB Agents is now accepting Letters of Intent for the 2027 cycle of the OutSmarting Osteosarcoma Research Grant, the program that has driven the fight against this rare paediatric bone cancer since its founding in 2017.
Powered by MIB Agents’ Family Funds, the grant program has already fueled significant discovery, awarding $2.9 million to 37 dedicated investigators working to advance osteosarcoma research.
For 2027, the program will offer two funding mechanisms. The OutSmarting Osteosarcoma Hero Award provides $100,000 in grant funding, while the OutSmarting Osteosarcoma Young Investigator (YI) Hope Award offers $50,000 to support early-career researchers. Both awards are open to investigators based in the United States and Canada.
Key Dates
- LOI Submission Period Opens: September 9, 2026
- Letter of Intent Due: October 16, 2026, at 11:59 pm ET
- Full Application Due: January 25, 2027
- Grant Period: July 1, 2027 – June 30, 2028
Investigators interested in applying should plan to submit a Letter of Intent during the September–October window ahead of the January 2027 full application deadline.
